Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 1/2013

Open Access 01-03-2013 | Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections

Author: C. Orla Morrissey

Published in: Current Fungal Infection Reports | Issue 1/2013

Login to get access

Abstract

Invasive fungal infections (IFI) are a significant cause of morbidity and mortality in the immunocompromised. The traditional diagnostic methods of culture and histological examination lack sensitivity and often only make a diagnosis late when the fungal burden is high, reducing the chances of cure even with the availability of new more potent and less toxic antifungal agents. New non-culture-based serological and PCR assays have been developed. These appear more sensitive and are able to make an earlier diagnosis as compared with traditional diagnostic methods. Early diagnosis is central to reducing IFI-related morbidity and mortality. This review describes the diagnostic potential of the new serological and PCR assays and outlines how these assays have been incorporated into algorithms to improve the management of IFI.
Literature
1.
Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. [published erratum appears in Clin Infect Dis 2004, 39:1093]. Clin Infect Dis. 2004;2004(39):309–17.CrossRef
2.
Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–77.PubMedCrossRef
3.
Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: Analysis of multicenter prospective antifungal therapy (PATH) alliance registry. Clin Infect Dis. 2009;48:265–73.PubMedCrossRef
4.
• Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17:1882–89. This recent national prospective surveillance study from France provides some of the most up to date data on the incidence of invasive aspergillosis (IA) and 12-week overall mortality rates. No significant change in incidence was seen over time. Patients with chronic lymphoproliferative disorders were noted to have emerged as a new group at high-risk for IA.PubMedCrossRef
5.
• Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–30. This paper describes the burden of cryptococcosis globally and notes that the majority of cases occur in developing countries, especially Sub-Saharan Africa.PubMedCrossRef
6.
Tong KB, Lau CJ, Murtagh K, et al. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis. 2009;13:24–36.PubMedCrossRef
7.
Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modelling approach. Antimicrob Agents Chemother. 2011;55:1953–60.PubMedCrossRef
8.
von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341–47.CrossRef
9.
Stevens DA. Diagnosis of fungal infections; current status. J Antimicrob Chemother. 2002;49 Suppl 1:11–9.PubMedCrossRef
10.
•• Lamoth F, Cruciani M, Mengoli C, et al. Beta-glucan antigenemia for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43. A meta-analysis of the performance of beta-D-glucan in a specific population of patients undergoing chemotherapy for hemato-oncological malignancies showed that the use of two positive results for diagnosis had high specificity.PubMedCrossRef
11.
Senn L, Robinson JO, Schmidt S, et al. 1,3-beta-d-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46:878–85.PubMedCrossRef
12.
Hachem RY, Kontoyiannis DP, Chemaly RF. et al.:Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2009;47:129–33.PubMedCrossRef
13.
de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infection Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.PubMedCrossRef
14.
• Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846–54. A very recent review of the available data on biomarkers for the diagnosis of invasive fungal infections.PubMedCrossRef
15.
•• Posteraro B, De Pascale G, Tumbarello M, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1 → 3)-β-D-glucan assay, Candida score and colonization index. Crit Care. 2011;15:R249. A prospective comparison of beta-D-glucan to the Candida score and the colonisation index which showed that beta-D-glucan is more sensitive and makes a diagnosis of invasive candidiasis 1–3 days prior to culture-based diagnosis.PubMedCrossRef
16.
Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–33.PubMedCrossRef
17.
Pittet D, Monod M, Sute PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–58.PubMedCrossRef
18.
Theel ES, Jespersen DJ, Igbal S, et al. Detection of (1,3)-β-D: -glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2012, Sept 1. [Epub ahead of print].
19.
•• Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time PCR, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240–48. A prospective comparison of Candida real-time PCR, β-D-glucan assay, and blood cultures which showed that PCR in particular improves the ability of blood cultures to diagnose invasive candidiasis, picking up cases missed by blood cultures.PubMedCrossRef
20.
Karageorgopoulos DE, Qu Jm, Korbila IP, et al. Accuracy of β-d-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2011, Dec 29. [Epub ahead of print].
21.
Mikulska M, Calandra T, Sanguinetti M, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14:R222.PubMedCrossRef
22.
• Lunel FM, Donnelly JP, van der Lee HA, et al. Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infections in patients undergoing myeloablative therapy. Med Mycol. 2011;49:848–55. The new Candida antigen and antibody assays were compared to the old assays using a collection of serum samples from patients with microbiologically proven invasive candidiasis and control patients. The new assays were not more sensitive but specificity was reduced as a result of detection of mannan antigen in the serum of cases of superficial candidiasis by the new antigen assay.PubMed
23.
Arendrup MC, Bergmann OJ, Larsson L, et al. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect. 2010;16:855–62.PubMed
24.
Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis. 2008;27:245–51.PubMedCrossRef
25.
Maertens JA, Klont R, Masson C, et al. Optimization of the cut-off for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. 2007;44:1329–36.PubMedCrossRef
26.
Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis. 2006;42:1417–27.PubMedCrossRef
27.
Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002;186:1297–306.PubMedCrossRef
28.
Boutboul F, Alberti C, Leblanc T, et al. Invasive Aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002;34:939–43.PubMedCrossRef
29.
Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications. Clin Infect Dis. 2008;46:1412–22.PubMedCrossRef
30.
Fortun J, Martin-Davila P, Alvarez ME, et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation. 2009;87:256–60.PubMedCrossRef
31.
Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant. 2004;4:796–802.PubMedCrossRef
32.
Huang YT, Hung CC, Liao CH, et al. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol. 2009;45:2858–22.CrossRef
33.
•• Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One. 2012;7:e43347. This study is a meta-analysis of the performance of galactomannan (GM) enzyme-linked immunoassay for the diagnosis of invasive aspergillosis in bronchoalveolar lavage (BAL) fluid. Using a cut-off of 1.0 the GM assay had higher sensitivity in BAL as compared with serum.PubMedCrossRef
34.
Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–69.PubMedCrossRef
35.
Frank UK, Nishimura SL, et al. Evaluation of an enzyme immunoassay for detection of cryptococcal capsular polysaccharide antigen in serum and cerebrospinal fluid. J Clin Microbiol. 1993;31:97–101.PubMed
36.
Tanner DC, Weinstein MP, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994;32:1680–84.PubMed
37.
Feldmesser M, Harris C, et al. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis. 1996;23:827–30.PubMedCrossRef
38.
Saha DC, Xess I, Jain N. Evaluation of conventional & serological methods for rapid diagnosis of cryptococcosis. Ind J Med Res. 2008;127:483–88.
39.
•• Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of Cryptococcosis. Clin Infect Dis. 2011;53:321–25. This study shows that a novel cryptococcal lateral flow assay performs as well as the traditional diagnostic assays. In addition, it is economical, rapid and easy to perform. It has potential for use as a point-of-care test in resource-limited settings.PubMedCrossRef
40.
Lau A, Chen S, Sleiman S, Sorrell T. Current status and future perspectives on molecular and serological methods in diagnostic mycology. Future Microbiol. 2009;4:1185–222.PubMedCrossRef
41.
Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665–70.PubMedCrossRef
42.
Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis. 2001;33:1621–27.PubMedCrossRef
43.
Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:89–96.PubMedCrossRef
44.
Suarez F, Lortholary O, Buland S, et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol. 2008;46:3772–77.PubMedCrossRef
45.
• White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol. 2010;48:1231–40. This multi-center laboratory study identifies the factors necessary to optimize and standardize Aspergillus PCR for use in clinical studies.PubMedCrossRef
46.
White PL, Perry MD, Loeffler J, et al. Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol. 2010;48:3753–55.PubMedCrossRef
47.
Cuenca-Estrella M, Meije Y, Diaz-Pedroche C, et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia. J Clin Microbiol. 2009;47:379–84.PubMedCrossRef
48.
Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction –ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis. 2006;193:741–47.PubMedCrossRef
49.
•• Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012;89:120–27. This is a multicenter comparison of Aspergillus PCR and galactomannan (GM) enzyme-linked immunoassay for the diagnosis of invasive aspergillosis in bronchoalveolar lavage (BAL) fluid. The optimal cut-off for GM in BAL was determined in this study as 0.5 and positive results for both PCR and GM made a diagnosis of invasive aspergillosis high likely.PubMedCrossRef
50.
Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis. 2001;33:1504–12.PubMedCrossRef
51.
Lass-Flörl C, Aigner J, Gunsilius E, et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol. 2001;113:180–84.PubMedCrossRef
52.
Lass-Flörl C, Speth C, Mayr A, et al. Diagnosing and monitoring of invasive aspergillosis during antifungal therapy by polymerase chain reaction: an experimelntal study in mice. Diagn Microbiol Infect Dis. 2003;47:569–72.PubMedCrossRef
53.
Ferns RB, Fletcher H, Bradley S, et al. The prospective evaluation of a nested polymerase chain reaction assay for the early detection of Aspergillus infection in patients with leukaemia or undergoing allograft treatment. Br J Haematol. 2002;119:720–25.PubMedCrossRef
54.
Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCycler™ -mediated polymerase chain reaction assay, a nested –PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;125:196–202.PubMedCrossRef
55.
Lass-Flörl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol. 2004;42:4154–57.PubMedCrossRef
56.
Halliday C, Hoile R, Sorrell T, et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplant and patients with acute leukaemia. Br J Haematol. 2006;132:478–86.PubMed
57.
White PL, Perry MD, Moody A, et al. Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive Aspergillosis. J Clin Microbiol. 2011;49:169–74.
58.
Hanson KE, Pfeiffer CD, Lease ED, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One. 2012;7:e42282.PubMedCrossRef
59.
Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high-risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis. 2005;41:1242–50.PubMedCrossRef
60.
Barnes RA, White PL, Bygrave C, et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol. 2009;62:64–9.PubMedCrossRef
61.
Dignan FL, Evans SO, Ethell ME, et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant. 2009;44:51–6.PubMedCrossRef
62.
Aguilar-Guisado M, Espigado I, Cordero E, et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant. 2010;45:159–64.PubMedCrossRef
63.
Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile neutropenic patients: A randomized, controlled trial. Clin Infect Dis. 2009;48:1042–51.PubMedCrossRef
64.
Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant. 2009;43:553–61.PubMedCrossRef
65.
Tan BH, Low JG, Chlebicka NL, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis. 2011;15:350–56.CrossRef
66.
Blennow O, Remberger M, Klingspor L, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45:1710–18.PubMedCrossRef
67.
• Meya DB, Manabe YC, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448–55. This study demonstrates the effectiveness of early diagnosis and treatment of cryptococcal disease.PubMedCrossRef
68.
Jarvis JN, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856–62.PubMedCrossRef
69.
Micol R, et al. Prevalence, determinants of positivity and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555–59.PubMedCrossRef
Metadata
Title
Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections
Author
C. Orla Morrissey
Publication date
01-03-2013
Publisher
Current Science Inc.
Published in
Current Fungal Infection Reports / Issue 1/2013
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-012-0128-4

Other articles of this Issue 1/2013

Current Fungal Infection Reports 1/2013 Go to the issue

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Animal Models In Mycology: What Have We Learned Over The Past 30 Years

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing

Current Management of Fungal Infections (Luis Ostrosky-Zeichner, Section Editor)

How I Treat Histoplasmosis

Pediatric Fungal Infections (T Lehrnbecher, Section Editor)

Primary and Secondary Antifungal Prophylaxis in the Immunocompromised Child: Where do we Stand?

Pediatric Fungal Infections (T Lehrnbecher, Section Editor)

The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children

Invited Commentary

Invasive Fungal Infections: A Continuing Challenge Report from the 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 24–27 July 2012
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits